Budesonide/formoterol pressurized metered-dose inhaler versus budesonide: A randomized controlled trial in black patients with asthma

Journal of Asthma

Volumn 49, Issue 1, 2012, Pages 70-77

  Spector, Sheldon L ^a   Martin, Ubaldo J ^b   Uryniak, Tom ^b   O'Brien, Christopher D ^b  

^a California Allergy and Asthma Medical Group   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

African American; BUD DPI; BUD FM pMDI; efficacy; pharmacotherapy; race; safety

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; ASTHMA; CONTROLLED STUDY; CYST RUPTURE; DEATH; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY POWDER; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PHASE 4 CLINICAL TRIAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SYMPTOM; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; ASTHMA; BUDESONIDE; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; MULTIVARIATE ANALYSIS; REFERENCE VALUES; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855846621     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2011.633788     Document Type: Article

References (24)

1. American Lung Association. Trends in asthma morbidity and mortality. July 2011. Available at: http://www.lungusa.org. Accessed October 20, 2009.
2. Centers for Disease Control and Prevention. National Health Interview Survey (NHIS) data. 2008. Available at: http://www.cdc.gov/asthma/ nhis/08/table2-1.htm. Accessed September 29, 2010.
3. Ginde AA, Espinola JA, Camargo Jr. CA. Improved overall trends but persistent racial disparities in emergency department visits for acute asthma, 1993-2005. J Allergy Clin Immunol 2008; 122(2):313-318.
4. Lang DM, Polansky M, Sherman MS. Hospitalizations for asthma in an urban population: 1995-1999. Ann Allergy Asthma Immunol 2009; 103(2):128-133.
5. Zoratti EM, Havstad S, Rodriguez J, Robens-Paradise Y, Lafata JE, McCarthy B. Health service use by African Americans and Caucasians with asthma in a managed care setting. Am J Respir Crit Care Med 1998; 158(2):371-377. (Pubitemid 28378161)
6. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, the SMART Study Group. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129(1):15-26. (Pubitemid 43265239)
7. Bleecker ER, Yancey SW, Baitinger LA, Edwards LD, Klotsman M, Anderson WH, Dorinsky PM. Salmeterol response is not affected by β2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006; 118(4):809-816. (Pubitemid 44498754)
8. Bleecker ER, Postma DS, Lawrence RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to longacting β2-agonist therapy: a pharmacogenetic analysis of two randomized studies. Lancet 2007; 370(9605):2118-2125. (Pubitemid 350296302)
9. Bleecker ER, Nelson HS, Kraft M, Corren J, Meyers DA, Yancey SW, Anderson WH, Emmett AH, Ortega HG. β2-Receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010; 181(7):676-687.
10. Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, Ameredes BT, Castro M, Craig TJ, Denlinger L, Fahy JV, Jarjour N, Kazani S, Kim S, Kraft M, Lazarus SC, Lemanske Jr. RF, Markezich A, Martin RJ, Permaul P, Peters SP, Ramsdell J, Sorkness CA, Sutherland ER, Szefler SJ, Walter MJ, Wasserman SI, Israel E, for the National Heart, Lung, and Blood Institute s Asthma Clinical Research Network. Effect of β2-adrenergic receptor polymorphism on response to longacting β2 agonist in asthma (LARGE trial): a genotype-stratified, randomized, placebo-controlled, crossover trial. Lancet 2009; 374(9703):1754-1764.
11. Corren J, Korenblat PE, Miller CJ, O Brien CD, Mezzanotte WS. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin Ther 2007; 29(5):823-843. (Pubitemid 47225183)
12. Noonan M, Rosenwasser LJ, Martin P, O Brien CD, O Dowd L. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs 2006; 66(17): 2235-2254. (Pubitemid 44878530)
13. Bailey W, Castro M, Matz J, White M, Dransfield M, Yancey S, Ortega H. Asthma exacerbations in African Americans treated for1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. Curr Med Res Opin 2008; 24(6):1669-1682. (Pubitemid 351929065)
14. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136(1):225-244.
15. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995; 152(3):1107-1136.
16. Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the asthma quality of life questionnaire. Chest 1999; 115(5):1265-1270. (Pubitemid 29230632)
17. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the Asthma Control Test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113(1):59-65. (Pubitemid 38096162)
18. Schatz MS, Sorkness CA, Li JT, Marcus P, Murray JJ, Nathan RA, Kosinski M, Pendergraft TB, Jhingran P. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006; 117(3):549-556. (Pubitemid 43340217)
19. Centers for Disease Control and Prevention. Defining overweight and obesity. Available at: http://www.cdc.gov/obesity/defining.html. Accessed June 9, 2010.
20. Chervinsky P, Baker J, Bensch G, Parasuraman B, Boggs R, Martin P, O Dowd L. Patient-reported outcomes in adults with moderate to severe asthma after use of budesonide and formoterol administered via 1 pressurized metered-dose inhaler. Ann Allergy Asthma Immunol 2008; 101(5):463-473.
21. Murphy K, Nelson H, Parasuraman B, Boggs R, Miller C, O Dowd L. The effect of budesonide and formoterol in one pressurized metered-dose inhaler on patient-reported outcomes in adults with mild-to-moderate persistent asthma. Curr Med Res Opin 2008; 24(3):879-894. (Pubitemid 351428999)
22. Boulet L-P, Franssen E. Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir Med 2007; 101(11):2240-2247. (Pubitemid 47471412)
23. Lavoie KL, Bacon SL, Labrecque M, Cartier A, Ditto B. Higher BMI is associated with worse asthma control and quality of life but not asthma severity. Respir Med 2006; 100(4):648-657. (Pubitemid 43285752)
24. Gould W, Peterson EL, Karungi G, Zoratti A, Gaggin J, Toma G, Yan S, Levin AM, Yang JJ, Wells K, Wang M, Burke RR, Beckman K, Popadic D, Land SJ, Kumar R, SeiboldMA, Lanfear DE, Burchard EG, Williams LK. Factors predicting inhaled corticosteroid responsiveness in African American patients with asthma. J Allergy Clin Immunol 2010; 126(6):1131-1138.